Andrew H. Lane's most recent trade in Abbott Laboratories was a trade of 10,000 Common shares without par value done at an average price of $130.0 . Disclosure was reported to the exchange on Nov. 15, 2021.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Abbott Laboratories | Andrew H. Lane | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 130.01 per share. | 15 Nov 2021 | 10,000 | 76,087 (0%) | 0% | 130.0 | 1,300,090 | Common shares without par value |
Abbott Laboratories | Andrew H. Lane | EXECUTIVE VICE PRESIDENT | Sale of securities on an exchange or to another person at price $ 125.47 per share. | 27 Aug 2021 | 135,925 | 86,087 (0%) | 0% | 125.5 | 17,055,189 | Common shares without par value |
Abbott Laboratories | Andrew H. Lane | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2021 | 135,925 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrew H. Lane | EXECUTIVE VICE PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 27 Aug 2021 | 135,925 | 222,012 (0%) | 0% | 38.4 | 5,219,520 | Common shares without par value |
Abbott Laboratories | Andrew H. Lane | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 25,319 | 91,141 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Andrew H. Lane | EXECUTIVE VICE PRESIDENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 5,065 | 86,076 (0%) | 0% | 121.6 | 615,803 | Common shares without par value |
Abbott Laboratories | Andrew H. Lane | EXECUTIVE VICE PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 71,070 | 71,070 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrew H. Lane | Executive Vice President | Sale of securities on an exchange or to another person at price $ 92.00 per share. | 05 May 2020 | 80,000 | 65,822 (0%) | 0% | 92.0 | 7,360,104 | Common shares without par value |
Abbott Laboratories | Andrew H. Lane | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 41,268 | 0 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrew H. Lane | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.90 per share. | 05 May 2020 | 41,268 | 107,090 (0%) | 0% | 48.9 | 2,018,005 | Common shares without par value |
Abbott Laboratories | Andrew H. Lane | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 05 May 2020 | 38,732 | 145,822 (0%) | 0% | 38.4 | 1,487,309 | Common shares without par value |
Abbott Laboratories | Andrew H. Lane | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2020 | 38,732 | 135,925 | - | - | Option (right to buy) | |
Abbott Laboratories | Andrew H. Lane | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 1,659 | 66,187 (0%) | 0% | 0 | Common shares without par value | |
Abbott Laboratories | Andrew H. Lane | Executive Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.91 per share. | 01 Apr 2020 | 365 | 65,822 (0%) | 0% | 78.9 | 28,802 | Common shares without par value |